Summary
Cencora, Inc. (formerly AmerisourceBergen Corporation) reported a strong financial performance for the quarter ended March 31, 2003. Total revenue grew by 13% year-over-year to $11.2 billion, driven primarily by the Pharmaceutical Distribution segment. Net income increased by a significant 27% to $116.4 million, leading to diluted earnings per share of $1.03, up from $0.84 in the prior year. The company highlighted operational efficiencies and successful integration of recent acquisitions, which contributed to a 24% increase in operating income. The company also demonstrated robust cash flow generation, with operating activities providing $225.5 million in cash for the six-month period, despite a planned increase in merchandise inventories. Management expressed confidence in its ability to meet ongoing cash requirements through operational cash flows and existing debt agreements, supporting strategic investments and dividend payments.
Key Highlights
- 1Total revenue increased by 13% to $11.2 billion for the quarter ended March 31, 2003, compared to the prior year.
- 2Net income grew by 27% to $116.4 million, with diluted earnings per share rising to $1.03 from $0.84.
- 3Operating income saw a substantial 24% increase, indicating improved profitability and operational efficiencies.
- 4The Pharmaceutical Distribution segment remained the primary revenue driver, showing a 13% increase in revenue.
- 5The company completed two strategic acquisitions: US Bioservices Corporation and Bridge Medical, Inc., aimed at expanding service offerings and enhancing supply chain capabilities.
- 6The company's long-term debt increased, reflecting strategic financing for growth and acquisitions, with a notable issuance of $300 million in 7.25% senior notes.
- 7Cash flow from operations remained positive, providing $225.5 million for the six months ended March 31, 2003.